Free Trial

Nektar Therapeutics (NKTR) Competitors

Nektar Therapeutics logo
$24.65 -0.88 (-3.45%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$24.72 +0.08 (+0.30%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NKTR vs. PCRX, OMER, ASMB, CPIX, LLY, JNJ, ABBV, MRK, PFE, and BMY

Should you be buying Nektar Therapeutics stock or one of its competitors? The main competitors of Nektar Therapeutics include Pacira BioSciences (PCRX), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), and Bristol Myers Squibb (BMY). These companies are all part of the "pharmaceuticals" industry.

Nektar Therapeutics vs. Its Competitors

Pacira BioSciences (NASDAQ:PCRX) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

Pacira BioSciences has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

99.7% of Pacira BioSciences shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by insiders. Comparatively, 5.3% of Nektar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Pacira BioSciences has a net margin of -14.78% compared to Nektar Therapeutics' net margin of -152.49%. Pacira BioSciences' return on equity of 13.78% beat Nektar Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Pacira BioSciences-14.78% 13.78% 7.00%
Nektar Therapeutics -152.49%-329.54%-55.24%

Pacira BioSciences presently has a consensus price target of $26.44, suggesting a potential upside of 13.96%. Nektar Therapeutics has a consensus price target of $84.17, suggesting a potential upside of 241.45%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Nektar Therapeutics is more favorable than Pacira BioSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pacira BioSciences
1 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.33
Nektar Therapeutics
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00

In the previous week, Nektar Therapeutics had 17 more articles in the media than Pacira BioSciences. MarketBeat recorded 19 mentions for Nektar Therapeutics and 2 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.93 beat Nektar Therapeutics' score of 0.48 indicating that Pacira BioSciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pacira BioSciences
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nektar Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Pacira BioSciences has higher revenue and earnings than Nektar Therapeutics. Pacira BioSciences is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacira BioSciences$700.97M1.53-$99.56M-$2.28-10.18
Nektar Therapeutics$98.43M3.11-$118.96M-$9.60-2.57

Summary

Pacira BioSciences beats Nektar Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Nektar Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NKTR vs. The Competition

MetricNektar TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$307.20M$2.43B$5.56B$9.04B
Dividend YieldN/A1.78%5.24%4.01%
P/E Ratio-2.579.1027.6120.24
Price / Sales3.11680.45417.30118.22
Price / CashN/A158.5936.8958.10
Price / Book4.994.588.035.67
Net Income-$118.96M$31.34M$3.18B$249.21M
7 Day Performance-4.31%3.25%2.93%3.28%
1 Month Performance143.53%7.08%3.75%5.55%
1 Year Performance27.39%0.17%35.20%21.09%

Nektar Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NKTR
Nektar Therapeutics
4.587 of 5 stars
$24.65
-3.4%
$84.17
+241.4%
+26.4%$307.20M$98.43M-2.57220Analyst Revision
High Trading Volume
PCRX
Pacira BioSciences
3.4572 of 5 stars
$23.88
-3.0%
$26.44
+10.8%
+7.1%$1.11B$700.97M-10.47720
OMER
Omeros
3.6736 of 5 stars
$3.26
-3.4%
$18.00
+451.5%
-17.5%$190.71MN/A-1.23210
ASMB
Assembly Biosciences
3.664 of 5 stars
$17.53
+1.9%
$33.00
+88.3%
+49.4%$134.85M$28.52M-2.83100Trending News
CPIX
Cumberland Pharmaceuticals
0.5799 of 5 stars
$3.37
+2.1%
N/A+105.9%$50.04M$37.87M-13.3880News Coverage
LLY
Eli Lilly and Company
4.9885 of 5 stars
$784.89
+0.9%
$1,011.61
+28.9%
-13.2%$740.58B$45.04B63.5847,000Trending News
JNJ
Johnson & Johnson
4.8448 of 5 stars
$152.01
-0.1%
$170.88
+12.4%
+7.0%$365.71B$88.82B16.91138,100Positive News
ABBV
AbbVie
4.9035 of 5 stars
$186.43
+0.5%
$211.29
+13.3%
+15.7%$328.96B$56.33B79.2555,000Trending News
Analyst Revision
MRK
Merck & Co., Inc.
4.9962 of 5 stars
$79.81
-0.6%
$109.19
+36.8%
-35.7%$200.13B$64.17B11.6075,000Positive News
PFE
Pfizer
4.9763 of 5 stars
$24.22
-0.4%
$29.17
+20.4%
-8.1%$137.50B$62.46B17.5381,000Trending News
BMY
Bristol Myers Squibb
4.9456 of 5 stars
$46.75
-0.6%
$58.00
+24.1%
+17.4%$95.05B$48.30B17.4934,100Positive News

Related Companies and Tools


This page (NASDAQ:NKTR) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners